Data Sources

The Sabin Vaccine Institute, Inc. (Sabin) is a non-profit public 501(c)(3) organization dedicated to continuing the work of Dr. Albert B. Sabin in realizing the full and enormous potential of vaccines to prevent disease and suffering. In support of this goal, Sabin has made a concerted effort to provide available, up-to-date information about the diseases we fight from a variety of credible sources, including its own scientific research.

For suggested updates or resources Sabin should consider including in its archives, please email them to sabin@sabin.org.

DISEASES WE FIGHT

• Ascariasis
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-551

• Hookworm
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-551

• HPV
  Source: International Agency for Research on Cancer GLOBOCAN 2002 study

• Lymphatic Filariasis
  Source: Lymphatic Filariasis Elimination Programme
  Map Production: Public Health Mapping and GIS
  Communicable Diseases (CDS) World Health Organization, 2006

• Onchocerciasis
  Source: Lymphatic Filariasis Elimination Programme
  Map Production: Public Health Mapping Group
  Communicable Diseases (CDC)
  World Health Organization, August 2002

• Pneumococcal Disease
  Source: UNICEF and WHO publication: PNEUMONIA | The Forgotten Killer of Children

• Rotavirus
  Source: World Health Organization, 2004
  Department of Immunization, Vaccines & Biologicals (IVB)

• Schistosomiasis
  Source: World Health Organization

• Trachoma
  Source: World Health Organization;
  World map showing distribution of Trachoma; 2005

• Trichuriasis
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-551

 
VACCINE DEVELOPMENT

• Prevalence of Hookworm
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-55

• Prevalence of Schistosomiasis
  Source: World Health Organization

 
ADVOCACY & EDUCATION

• Prevalence of HPV
  Source: International Agency for Research on Cancer GLOBOCAN 2002 study

• Prevalence of Rotavirus
  Source: World Health Organization, 2004
  Department of Immunization, Vaccines & Biologicals (IVB)

• Prevalence of Pneumococcal Disease
  Source: UNICEF and WHO publication: PNEUMONIA | The Forgotten Killer of Children

 
GLOBAL NETWORK

• Prevalence of Ascariasis
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-551

• Prevalence of Hookworm
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-551

• Prevalence of Lymphatic Filariasis
  Source: Lymphatic Filariasis Elimination Programme
  Map Production: Public Health Mapping and GIS
  Communicable Diseases (CDS)
  World Health Organization, 2006

• Prevalence of Onchocerciasis
  Source: Lymphatic Filariasis Elimination Programme
  Map Production: Public Health Mapping Group
  Communicable Diseases (CDC)
  World Health Organization, August 2002

• Prevalence of Schistosomiasis
  Source: World Health Organization

• Prevalence of Trachoma
  Source: World Health Organization; World map showing distribution of Trachoma; 2005

• Prevalence of Trichuriasis
  Source: de Silva et al. 2003. Trends in Parasitology 19, 547-551

 
LIFE EXPECTANCY AND PRODUCTIVITY STATEMENT ON CHILDHOOD VACCINATION
Sources:

• Matthews Z, Diamond I. The Expanded Programme on Immunisation: mortality consequences and demographic impact in developing countries. Genus, 1999, 55: 73-100.
• Bloom DE, Canning D, Sevilla J. The effect of health on economic growth: A production function approach. World Development, 2004, 32,1.

SUSTAINABLE IMMUNIZATION FINANCING

• Vaccine-Preventable Diseases. In: Jamison et al. (eds): Disease Control Priorities in Developing Countries. 2006; Second Edition. Washington, DC: The World Bank, 389-411. Brenzel L, Wolfson LJ, Fox-Rushby J, Miller M, Halsey, NA. View full text.
• Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa. Vaccine, 2004; 22(25–26): 3419–26. Uzicanin A, Zhou F, Eggers R, Webb E, Strebel P. Link to full text.
• The Value of Vaccination. World Economics, 2005; 6(3): 15-40. Bloom D, Canning D, Weston M. View full text.
• Costs and benefits of polio eradication: a long-run global perspective. Vaccine, 2003; 21(7-8):702-5. Khan MM, Ehreth J. Link to full text